Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up (Q34166349)

31 July 2017

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up (English)

1 reference

31 July 2017

1 reference

Evgeny Krupitsky

1

1 reference

31 July 2017

Andrey Burakov

2

1 reference

31 July 2017

Tatyana Romanova

3

1 reference

31 July 2017

Igor Dunaevsky

4

1 reference

31 July 2017

Rick Strassman

5

1 reference

31 July 2017

Alexander Grinenko

6

1 reference

31 July 2017

language of work or name

1 reference

1 December 2002

1 reference

Journal of Substance Abuse Treatment

31 July 2017

1 reference

31 July 2017

23

1 reference

31 July 2017

4

1 reference

31 July 2017

273-283

1 reference

Antidepressant effects of ketamine in depressed patients

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Ibogaine neurotoxicity assessment: electrophysiological, neurochemical, and neurohistological methods

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

LSD in the Treatment of Alcoholics*

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Medication development of ibogaine as a pharmacotherapy for drug dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Human psychopharmacology of N,N-dimethyltryptamine

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

A SELF-RATING DEPRESSION SCALE

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2802%2900275-1

7 January 2021

10.1016/S0740-5472(02)00275-1

Identifiers

DOI

1 reference

31 July 2017

1 reference